AI in Clinical Decision Support: Compliance Requirements for Healthcare Providers

Why Clinical Decision Support Is High-Risk

Clinical decision support (CDS) systems that use AI to recommend diagnoses, treatments, or risk scores fall squarely within the EU AI Act's high-risk category. Annex III, Area 5(a) explicitly lists AI systems intended to be used for evaluating health-related outcomes. Any AI system that influences medical decisions affecting patient safety triggers high-risk obligations under Article 6.

In the United States, the FDA's Digital Health Center of Excellence has developed its framework for AI/ML-enabled Software as a Medical Device. The Total Product Life Cycle approach means CDS systems need ongoing monitoring even after initial clearance, particularly when the algorithm continues learning from new patient data.

Key Compliance Requirements

For EU-based healthcare providers deploying CDS systems, compliance includes a conformity assessment under Article 43 before go-live, typically requiring a notified body. Article 14 requires human oversight by clinicians who understand the system's capabilities and limitations. Article 9 mandates a risk management system throughout the CDS lifecycle.

Data governance under Article 10 is critical in healthcare. Training data must be representative across patient demographics. A CDS system trained predominantly on data from one population group may produce unreliable outputs for other groups, creating both clinical and legal risk.

Practical Implementation

Healthcare organisations should begin with a thorough inventory of all AI-assisted clinical tools currently in use, including those embedded in electronic health record systems. Many organisations discover AI components integrated into existing platforms without formal compliance review.

Establish a clinical AI governance committee including representatives from clinical practice, IT, legal, and patient safety. This committee should own the risk management process required under Article 9 and conduct the fundamental rights impact assessment under Article 27 for public-sector providers.

Post-Market Monitoring

Article 72 requires post-market monitoring for all high-risk AI systems. In healthcare, this means tracking clinical outcomes linked to AI-assisted decisions, monitoring for algorithmic drift, and establishing clear incident reporting channels. Serious incidents must be reported under Article 73 within 15 days.

The practical challenge is integrating AI monitoring into existing patient safety and quality assurance frameworks. Rather than building a parallel system, the most effective approach extends current clinical governance to include AI-specific metrics.

This article is for informational purposes only and does not constitute legal advice. Regulatory requirements change frequently — verify current rules with official sources. Built by Sawai Gyoseishoshi Office, Hiroshima, Japan.